Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (742)	2/7/2003 8:58:28 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

RE: ML presentation. Nothing seriously new, but three note worth mentioning. 1. First time Schleifer mentioned active discussion re Axokine license. "Best friend or prospective best friends are several pharma's CEO" 2. IL-1 Trap partnering efforts progressed further, but they will not rush. (If terms are not good, my reading). 3. VEGF Trap, First time they mentioned promising early PI results (relative to DNA drug)and moving toward DME (after Eyetech-PFE deal). Bit late, but better ever than never. Miljenko